On January 30, 2025, the FDA approved suzetrigine (brand name Journavx) by Vertex Pharmaceuticals, marking the introduction of the first new class of pain medication in two decades. This medication aims to address moderate-to-severe pain while avoiding the addiction risks associated with opioids. Suzetrigine works by targeting the sodium channel Nav 1.8, specifically in pain neurons, making it a unique solution distinct from traditional opioid therapies. The approval responds to the urgent need for non-addictive pain management options, especially given the surge in opioid-related overdose deaths in recent years.
Suzetrigine, the first non-opioid painkiller approved by the FDA in decades, targets specific sodium channels, offering a new alternative amid the opioid crisis.
Suzetrigine works by controlling the flow of sodium in and out of pain neurons, ensuring effectiveness without the addictive risks associated with opioids.
Collection
[
|
...
]